102 related articles for article (PubMed ID: 8605586)
1. Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120.
Kuipers ME; Huisman JG; Swart PJ; de Béthune MP; Pauwels R; Schuitemaker H; De Clercq E; Meijer DK
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):419-29. PubMed ID: 8605586
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of anti-HIV activity of succinylated human serum albumin.
Kuipers ME; vd Berg M; Swart PJ; Laman JD; Meijer DK; Koppelman MH; Huisman H
Biochem Pharmacol; 1999 Apr; 57(8):889-98. PubMed ID: 10086322
[TBL] [Abstract][Full Text] [Related]
3. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
4. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers ME; Swart PJ; Meijer DK; Desmyter J; De Clercq E; Esté JA
AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1535-43. PubMed ID: 10580404
[TBL] [Abstract][Full Text] [Related]
5. The influence of charge clustering on the anti-HIV-1 activity and in vivo distribution of negatively charged albumins.
Beljaars L; Floris R; Berkhout B; Smit C; Meijer DK; Molema G
Biochem Pharmacol; 2002 May; 63(9):1663-73. PubMed ID: 12007569
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
Neurath AR; Strick N; Debnath AK
J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
Debnath AK; Jiang S; Strick N; Lin K; Haberfield P; Neurath AR
J Med Chem; 1994 Apr; 37(8):1099-108. PubMed ID: 8164251
[TBL] [Abstract][Full Text] [Related]
8. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins.
Jansen RW; Molema G; Pauwels R; Schols D; De Clercq E; Meijer DK
Mol Pharmacol; 1991 Jun; 39(6):818-23. PubMed ID: 2051994
[TBL] [Abstract][Full Text] [Related]
9. Single basic amino acid substitutions at position 302 or 320 in the V3 domain of HIV type 1 are not sufficient to alter the antiviral activity of dextran sulfate and heparin.
Okada T; Gurney ME
AIDS Res Hum Retroviruses; 1995 May; 11(5):571-5. PubMed ID: 7576913
[TBL] [Abstract][Full Text] [Related]
10. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4.
Harrop HA; Rider CC
Glycobiology; 1998 Feb; 8(2):131-7. PubMed ID: 9451022
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV-1 activity of combinations and covalent conjugates of negatively charged human serum albumins (NCAs) and AZT.
Kuipers ME; Swart PJ; Witvrouw M; Esté JA; Reymen D; De Clercq E; Meijer DK
J Drug Target; 1999; 6(5):323-35. PubMed ID: 10342381
[TBL] [Abstract][Full Text] [Related]
12. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.
Este JA; Schols D; De Vreese K; Van Laethem K; Vandamme AM; Desmyter J; De Clercq E
Mol Pharmacol; 1997 Jul; 52(1):98-104. PubMed ID: 9224818
[TBL] [Abstract][Full Text] [Related]
13. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion.
Rosen O; Sharon M; Quadt-Akabayov SR; Anglister J
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):13950-5. PubMed ID: 16966601
[TBL] [Abstract][Full Text] [Related]
14. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
[TBL] [Abstract][Full Text] [Related]
15. CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments.
Meshcheryakova D; Andreev S; Tarasova S; Sidorova M; Vafina M; Kornilaeva G; Karamov E; Khaitov R
Mol Immunol; 1993 Aug; 30(11):993-1001. PubMed ID: 8102473
[TBL] [Abstract][Full Text] [Related]
16. The V3 loop of human immunodeficiency virus type-1 envelope protein is a high-affinity ligand for immunophilins present in human blood.
Endrich MM; Gehring H
Eur J Biochem; 1998 Mar; 252(3):441-6. PubMed ID: 9546659
[TBL] [Abstract][Full Text] [Related]
17. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
Cormier EG; Dragic T
J Virol; 2002 Sep; 76(17):8953-7. PubMed ID: 12163614
[TBL] [Abstract][Full Text] [Related]
18. Short synthetic peptides derived from viral proteins compete with HIV gp120 for the binding to CD4 receptors.
Chersi A; Pugliese O; Federico A; Viora M
Viral Immunol; 2000; 13(4):547-54. PubMed ID: 11192301
[TBL] [Abstract][Full Text] [Related]
19. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.
Moulard M; Lortat-Jacob H; Mondor I; Roca G; Wyatt R; Sodroski J; Zhao L; Olson W; Kwong PD; Sattentau QJ
J Virol; 2000 Feb; 74(4):1948-60. PubMed ID: 10644368
[TBL] [Abstract][Full Text] [Related]
20. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
